Lomaira and Belviq XR Are New C-IV Meds for Weight Loss

Please see the February 2020 FDA recommendation to remove Belviq and Belviq XR from the market.

Lomaira and Belviq XR will offer new options for weight loss.

Lomaira (loh-MER-uh) is a "low-dose" version of phentermine. It contains phentermine 8 mg...instead of 15, 30, or 37.5 mg.

Expect most patients on Lomaira to take up to one tab three times daily 30 minutes before meals...instead of once or twice daily like higher-strength phentermine products.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote